mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.
Previous Post
Population Health Management Programs in CKD: Promise and Pitfalls
Next Post
Monocyte-to-Lymphocyte Ratio Linked With Functional Status in CLL
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago